<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2025-3192</article-id><article-id custom-type="edn" pub-id-type="custom">TCNCNG</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-3192</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CURRENT QUESTIONS OF CLINICAL PHARMACOLOGY</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ  ВОПРОСЫ  КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИ</subject></subj-group></article-categories><title-group><article-title>Direct methods for assessing adherence to antihypertensive therapy: witnessed intake and therapeutic drug monitoring</article-title><trans-title-group xml:lang="ru"><trans-title>Прямые методы оценки приверженности к антигипертензивной терапии: контролируемый прием препаратов и терапевтический лекарственный мониторинг</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3664-5383</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ионов</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ionov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ионов Михаил Васильевич </p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Mikhail V. Ionov </p><p>Saint-Petersburg </p></bio><email xlink:type="simple">mikeionov90@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3176-0606</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Емельянов</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Emelyanov</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Емельянов Игорь Витальевич </p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Igor V. Emelyanov </p><p>Saint-Petersburg </p></bio><email xlink:type="simple">iemelyanov@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8169-7812</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Конради</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Konradi</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Конради Александра Олеговна </p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Alexandra O. Konradi </p><p>Saint-Petersburg </p></bio><email xlink:type="simple">ahleague@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр им. В. А. Алмазова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>22</day><month>08</month><year>2025</year></pub-date><volume>21</volume><issue>3</issue><fpage>234</fpage><lpage>243</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ionov M.V., Emelyanov I.V., Konradi A.O., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Ионов М.В., Емельянов И.В., Конради А.О.</copyright-holder><copyright-holder xml:lang="en">Ionov M.V., Emelyanov I.V., Konradi A.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/3192">https://www.rpcardio.online/jour/article/view/3192</self-uri><abstract><p>Low adherence to therapy is one of the main causes of pseudo-resistant arterial hypertension (AH), associated with an increased risk of cardiovascular complications and higher direct and indirect medical costs. Adherence assessment is a crucial step in the management of patients with uncontrolled AH, particularly when therapeutic resistance is suspected. There is no "gold standard" for assessing therapy adherence. Therefore, beyond indirect methods (though simple, they are relatively unreliable), direct approaches are increasingly being utilized. These include witnessed medication intake by medical personnel — conducted alongside repeated ambulatory blood pressure monitoring using portable devices or repeated measurements by a specialist — and therapeutic drug monitoring of medications or their metabolites in biological fluids using ultra-high-performance liquid chromatography-tandem mass spectrometry. This narrative review summarizes key findings from studies on the application of these methods, outlines their respective advantages and limitations, and provides practical recommendations for their integration into everyday clinical practice. Early and simultaneous implementation of these strategies can help avoid unnecessary complex and costly diagnostic procedures in some cases and allows for more accurate identification of truly resistant AH – a patient group of scientific and clinical relevance. The use of these approaches improves the cost-effectiveness of treatment, helps uncover non-medical barriers to adherence, and strengthens the physician–patient relationship.</p></abstract><trans-abstract xml:lang="ru"><p>Низкая приверженность к терапии – одна из основных причин псевдорезистентной артериальной гипертензии (АГ), сопряжена с повышением риска сердечно-сосудистых осложнений и увеличением прямых и непрямых медицинских затрат. Оценка приверженности является важным элементом в ведении пациентов с неконтролируемой АГ, особенно при подозрении на устойчивость к терапии. «Золотого стандарта» оценки приверженности к терапии нет и поэтому, кроме непрямых методов, хотя и простых, но довольно ненадежных, в последнее время все чаще используются прямые способы — контроль приема препаратов в присутствии медперсонала, которые проводятся на фоне повторного мониторирования артериального давления при помощи портативных устройств или повторных его измерений специалистом, а также терапевтический мониторинг лекарственных препаратов или метаболитов в биологических жидкостях с использованием ультра-высокоэффективной жидкостной хроматографии с тандемной масс-спектрометрией. В данном описательном обзоре представлены ключевые результаты исследований по применению этих методов, рассмотрены их ограничения и преимущества, а также даны практические рекомендации по внедрению этих подходов в повседневную клиническую практику. Симультанное и как можно более раннее их применение позволяет исключить в ряде случаев необходимость в дополнительных сложных и затратных лечебно-диагностических процедурах, а также более точно и надежно выделить группу пациентов с истинно резистентной АГ — когорту, которая представляет наибольший научно-практический интерес. Использование рассмотренных подходов повышает клинико-экономическую эффективность лечения, помогает выявить парамедицинские проблемы и укрепляет взаимодействие между врачом и пациентом.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>псевдорезистентная артериальная гипертензия</kwd><kwd>резистентная артериальная гипертензия</kwd><kwd>приверженность</kwd><kwd>персистенция</kwd><kwd>непосредственный контроль приема препаратов</kwd><kwd>хроматография</kwd><kwd>масс-спектрометрия</kwd><kwd>терапевтический лекарственный мониторинг</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>pseudo-resistant arterial hypertension</kwd><kwd>resistant arterial hypertension</kwd><kwd>adherence</kwd><kwd>persistence</kwd><kwd>witnessed drug intake</kwd><kwd>chromatography</kwd><kwd>mass spectrometry</kwd><kwd>therapeutic drug monitoring</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках реализации проекта государственного задания «Разработка персонализированного комплексного подхода к ведению пациентов с неконтролируемой эссенциальной артериальной гипертензией с применением прямых методов оценки приверженности к лечению и телемедицинских технологий», рег. номер ЕГИСУ НИОКТР 125031904080-9.</funding-statement><funding-statement xml:lang="en">The study was carried out as part of the implementation of the state assignment project «Development of a personalized comprehensive approach to the management of patients with uncontrolled essential arterial hypertension using direct methods of treatment adherence assessment and telemedicine technologies», registration number 125031904080-9.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80. DOI:10.1016/S0140-6736(21)01330-1. Erratum in: Lancet. 2022;399(10324):520. DOI:10.1016/S0140-6736(22)00061-7.</mixed-citation><mixed-citation xml:lang="en">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80. DOI:10.1016/S0140-6736(21)01330-1. Erratum in: Lancet. 2022;399(10324):520. DOI:10.1016/S0140-6736(22)00061-7.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Egan BM, Kjeldsen SE, Grassi G, et al. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? J Hypertens. 2019;37(6):1148-53. DOI:10.1097/HJH.0000000000002021.</mixed-citation><mixed-citation xml:lang="en">Egan BM, Kjeldsen SE, Grassi G, et al. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? J Hypertens. 2019;37(6):1148-53. DOI:10.1097/HJH.0000000000002021.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">de la Sierra A, Ruilope LM, Staplin N, et al. Resistant Hypertension and Mortality: An Observational Cohort Study. Hypertension. 2024;81(11):2350-6. DOI:10.1161/HYPERTENSIONAHA.124.23276.</mixed-citation><mixed-citation xml:lang="en">de la Sierra A, Ruilope LM, Staplin N, et al. Resistant Hypertension and Mortality: An Observational Cohort Study. Hypertension. 2024;81(11):2350-6. DOI:10.1161/HYPERTENSIONAHA.124.23276.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Buhnerkempe MG, Prakash V, Botchway A, et al. Adverse Health Outcomes Associated With Refractory and Treatment-Resistant Hypertension in the Chronic Renal Insufficiency Cohort. Hypertension. 2021:77(1):72-81. DOI:10.1161/HYPERTENSIONAHA.120.15064.</mixed-citation><mixed-citation xml:lang="en">Buhnerkempe MG, Prakash V, Botchway A, et al. Adverse Health Outcomes Associated With Refractory and Treatment-Resistant Hypertension in the Chronic Renal Insufficiency Cohort. Hypertension. 2021:77(1):72-81. DOI:10.1161/HYPERTENSIONAHA.120.15064.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014(11):CD000011. DOI:10.1002/14651858.CD000011.pub4.</mixed-citation><mixed-citation xml:lang="en">Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014(11):CD000011. DOI:10.1002/14651858.CD000011.pub4.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tajeu GS, Kent ST, Huang L, et al. Antihypertensive Medication Nonpersistence and Low Adherence for Adults &lt;65 Years Initiating Treatment in 2007-2014. Hypertension. 2019;74(1):35-46. DOI:10.1161/HYPERTENSIONAHA.118.12495.</mixed-citation><mixed-citation xml:lang="en">Tajeu GS, Kent ST, Huang L, et al. Antihypertensive Medication Nonpersistence and Low Adherence for Adults &lt;65 Years Initiating Treatment in 2007-2014. Hypertension. 2019;74(1):35-46. DOI:10.1161/HYPERTENSIONAHA.118.12495.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019;124(1):1124-40. DOI:10.1161/CIRCRESAHA.118.313220.</mixed-citation><mixed-citation xml:lang="en">Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019;124(1):1124-40. DOI:10.1161/CIRCRESAHA.118.313220.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120(16):1598-605. DOI:10.1161/CIRCULATIONAHA.108.830299.</mixed-citation><mixed-citation xml:lang="en">Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120(16):1598-605. DOI:10.1161/CIRCULATIONAHA.108.830299.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bochkareva EV, Butina EK, Kim IV, et al. Adherence to antihypertensive medication in Russia: a scoping review of studies on levels, determinants and intervention strategies published between 2000 and 2017. Arch Public Health. 2019;77:43. DOI:10.1186/s13690-019-0366-9.</mixed-citation><mixed-citation xml:lang="en">Bochkareva EV, Butina EK, Kim IV, et al. Adherence to antihypertensive medication in Russia: a scoping review of studies on levels, determinants and intervention strategies published between 2000 and 2017. Arch Public Health. 2019;77:43. DOI:10.1186/s13690-019-0366-9.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114-7. DOI:10.1136/bmj.39553.670231.25.</mixed-citation><mixed-citation xml:lang="en">Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114-7. DOI:10.1136/bmj.39553.670231.25.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary nonadherence to chronic disease medications: a meta-analysis. Patient Prefer Adherence. 2018;12:721-31. DOI:10.2147/PPA.S161151.</mixed-citation><mixed-citation xml:lang="en">Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary nonadherence to chronic disease medications: a meta-analysis. Patient Prefer Adherence. 2018;12:721-31. DOI:10.2147/PPA.S161151.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lee H, Yano Y, Cho SMJ, et al. Adherence to Antihypertensive Medication and Incident Cardiovascular Events in Young Adults With Hypertension. Hypertension. 2021;77(4):1341-9. DOI:10.1161/HYPERTENSIONAHA.120.16784.</mixed-citation><mixed-citation xml:lang="en">Lee H, Yano Y, Cho SMJ, et al. Adherence to Antihypertensive Medication and Incident Cardiovascular Events in Young Adults With Hypertension. Hypertension. 2021;77(4):1341-9. DOI:10.1161/HYPERTENSIONAHA.120.16784.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cutler RL, Fernandez-Llimos F, Frommer M, et al. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982. DOI:10.1136/bmjopen-2017-016982.</mixed-citation><mixed-citation xml:lang="en">Cutler RL, Fernandez-Llimos F, Frommer M, et al. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982. DOI:10.1136/bmjopen-2017-016982.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Parekh N, Ali K, Stevenson JM, et al. Incidence and cost of medication harm in older adults following hospital discharge: a multicentre prospective study in the UK. Br J Clin Pharmacol. 2018;84(8):1789-97. DOI:10.1111/bcp.13613.</mixed-citation><mixed-citation xml:lang="en">Parekh N, Ali K, Stevenson JM, et al. Incidence and cost of medication harm in older adults following hospital discharge: a multicentre prospective study in the UK. Br J Clin Pharmacol. 2018;84(8):1789-97. DOI:10.1111/bcp.13613.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Berra E, Azizi M, Capron A, et al. Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently TreatmentResistant Hypertension. Hypertension. 2016;68(2):297-306. DOI:10.1161/HYPERTENSIONAHA.116.07464.</mixed-citation><mixed-citation xml:lang="en">Berra E, Azizi M, Capron A, et al. Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently TreatmentResistant Hypertension. Hypertension. 2016;68(2):297-306. DOI:10.1161/HYPERTENSIONAHA.116.07464.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;(2):D000011. DOI:10.1002/14651858.CD000011.</mixed-citation><mixed-citation xml:lang="en">Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;(2):D000011. DOI:10.1002/14651858.CD000011.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19(11):1190-6. DOI:10.1016/j.amjhyper.2006.04.006.</mixed-citation><mixed-citation xml:lang="en">Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19(11):1190-6. DOI:10.1016/j.amjhyper.2006.04.006.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю., Драпкина О.М. Проблемные вопросы и разработка классификаций основных параметров качества и приверженности фармакотерапии. Часть I: приверженность пациентов к лечению. Кардиоваскулярная терапия и профилактика. 2023;22(6):3603] DOI:10.15829/17288800-2024-4268.</mixed-citation><mixed-citation xml:lang="en">Lukina YuV, Kutishenko NP, Martsevich SYu, Drapkina OM. Issues of concern and development of classifications of the main parameters of therapy quality and compliance. Part III: quality of pharmacotherapy. Cardiovascular Therapy and Prevention. 2023;22(6):3603. (In Russ.) DOI:10.15829/17288800-2024-4268.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Mukhtar O, Weinman J, Jackson SH. Intentional non-adherence to medications by older adults. Drugs Aging. 2014;31(3):149-57. DOI:10.1007/s40266-014-0153-9.</mixed-citation><mixed-citation xml:lang="en">Mukhtar O, Weinman J, Jackson SH. Intentional non-adherence to medications by older adults. Drugs Aging. 2014;31(3):149-57. DOI:10.1007/s40266-014-0153-9.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Morisky DE, Green LW, Levine DM. Concurrent and Predictive Validity of a SelfReported Measure of Medication Adherence. Medical Care. 1986;24(1):67-74. DOI:10.1097/00005650-198601000-00007.</mixed-citation><mixed-citation xml:lang="en">Morisky DE, Green LW, Levine DM. Concurrent and Predictive Validity of a SelfReported Measure of Medication Adherence. Medical Care. 1986;24(1):67-74. DOI:10.1097/00005650-198601000-00007.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Николаев Н.А., Скирденко Ю.П. Российский универсальный опросник количественной оценки приверженности к лечению (КОП-25). Клиническая фармакология и терапия. 2018;27(1):74-8]</mixed-citation><mixed-citation xml:lang="en">Nikolayev NA, Skirdenko YuP. Russian generic questionnaire for evaluation of compliance to drug therapy. Klinicheskaya Farmakolоgiya i Terapiya. 2018;27(1):74-8. (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the HillBone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000;15(3):90-6. DOI:10.1111/j.1751-7117.2000.tb00211.x.</mixed-citation><mixed-citation xml:lang="en">Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the HillBone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000;15(3):90-6. DOI:10.1111/j.1751-7117.2000.tb00211.x.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">El Alili M, Vrijens B, Demonceau J, et al. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol. 2016;82(1):268-79. DOI:10.1111/bcp.12942.</mixed-citation><mixed-citation xml:lang="en">El Alili M, Vrijens B, Demonceau J, et al. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol. 2016;82(1):268-79. DOI:10.1111/bcp.12942.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Sideri K, Cockbain J, Van Biesen W, et al. Digital pills for the remote monitoring of medication intake: a stakeholder analysis and assessment of marketing approval and patent granting policies. J Law Biosci. 2022;9(2):lsac029. DOI:10.1093/jlb/lsac029.</mixed-citation><mixed-citation xml:lang="en">Sideri K, Cockbain J, Van Biesen W, et al. Digital pills for the remote monitoring of medication intake: a stakeholder analysis and assessment of marketing approval and patent granting policies. J Law Biosci. 2022;9(2):lsac029. DOI:10.1093/jlb/lsac029.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res. 2012;12:270. DOI:10.1186/1472-6963-12-270.</mixed-citation><mixed-citation xml:lang="en">Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res. 2012;12:270. DOI:10.1186/1472-6963-12-270.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Park LG, Howie-Esquivel J, Dracup K. Electronic measurement of medication adherence. West J Nurs Res. 2015;37(1):28-49. DOI:10.1177/0193945914524492.</mixed-citation><mixed-citation xml:lang="en">Park LG, Howie-Esquivel J, Dracup K. Electronic measurement of medication adherence. West J Nurs Res. 2015;37(1):28-49. DOI:10.1177/0193945914524492.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tan dem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855- 61. DOI:10.1136/heartjnl-2013-305063.</mixed-citation><mixed-citation xml:lang="en">Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tan dem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855- 61. DOI:10.1136/heartjnl-2013-305063.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Polukhin NV, Nikolic TR, Ekkert NV, et al. The Analysis of the Context of Digital Access to Healthcare in Russia. Sustainability. 2023;15(3):2271. DOI:10.3390/su15032271.</mixed-citation><mixed-citation xml:lang="en">Polukhin NV, Nikolic TR, Ekkert NV, et al. The Analysis of the Context of Digital Access to Healthcare in Russia. Sustainability. 2023;15(3):2271. DOI:10.3390/su15032271.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Bourque G, Ilin JV, Ruzicka M, et al. Nonadherence Is Common in Patients With Apparent Resistant Hypertension: A Systematic Review and Meta-analysis. Am J Hypertens. 2023;36(7):394-403. DOI:10.1093/ajh/hpad013.</mixed-citation><mixed-citation xml:lang="en">Bourque G, Ilin JV, Ruzicka M, et al. Nonadherence Is Common in Patients With Apparent Resistant Hypertension: A Systematic Review and Meta-analysis. Am J Hypertens. 2023;36(7):394-403. DOI:10.1093/ajh/hpad013.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Ruzicka M, Leenen FHH, Ramsay T, et al. Use of Directly Observed Therapy to Assess Treatment Adherence in Patients With Apparent Treatment-Resistant Hypertension. JAMA Intern Med. 2019;179(10):1433-4. DOI:10.1001/jamainternmed.2019.1455.</mixed-citation><mixed-citation xml:lang="en">Ruzicka M, Leenen FHH, Ramsay T, et al. Use of Directly Observed Therapy to Assess Treatment Adherence in Patients With Apparent Treatment-Resistant Hypertension. JAMA Intern Med. 2019;179(10):1433-4. DOI:10.1001/jamainternmed.2019.1455.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Tian JH, Lu ZX, Bachmann MO, Song FJ. Effectiveness of directly observed treatment of tuberculosis: a systematic review of controlled studies. Int J Tuberc Lung Dis. 2014;18(9):1092-8. DOI:10.5588/ijtld.13.0867.</mixed-citation><mixed-citation xml:lang="en">Tian JH, Lu ZX, Bachmann MO, Song FJ. Effectiveness of directly observed treatment of tuberculosis: a systematic review of controlled studies. Int J Tuberc Lung Dis. 2014;18(9):1092-8. DOI:10.5588/ijtld.13.0867.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Hart JE, Jeon CY, Ivers LC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr. 2010;54(2):167-79. DOI:10.1097/QAI.0b013e3181d9a330. Erratum in: J Acquir Immune Defic Syndr. 2011;56(1):e37-8.</mixed-citation><mixed-citation xml:lang="en">Hart JE, Jeon CY, Ivers LC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr. 2010;54(2):167-79. DOI:10.1097/QAI.0b013e3181d9a330. Erratum in: J Acquir Immune Defic Syndr. 2011;56(1):e37-8.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Ducroix C, Choudey M, Cornic F, et al. Directly observed therapy (DOT) in a psychiatric consulting dispensary, long term practice and retrospective study of patients coming every day [abstract]. European Psychiatry. 2007;22(1):S207. DOI:10.1016/j.eurpsy.2007.01.688.</mixed-citation><mixed-citation xml:lang="en">Ducroix C, Choudey M, Cornic F, et al. Directly observed therapy (DOT) in a psychiatric consulting dispensary, long term practice and retrospective study of patients coming every day [abstract]. European Psychiatry. 2007;22(1):S207. DOI:10.1016/j.eurpsy.2007.01.688.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Ruzicka M, McCormick B, Leenen FHH, et al. Adherence to blood pressure-lowering drugs and resistant hypertension: should trial of direct observation therapy be part of preassessment for renal denervation? Can J Cardiol. 2013;29(12):1741. e1-3. DOI:10.1016/j.cjca.2013.07.678.</mixed-citation><mixed-citation xml:lang="en">Ruzicka M, McCormick B, Leenen FHH, et al. Adherence to blood pressure-lowering drugs and resistant hypertension: should trial of direct observation therapy be part of preassessment for renal denervation? Can J Cardiol. 2013;29(12):1741. e1-3. DOI:10.1016/j.cjca.2013.07.678.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Fadl Elmula FE, Hoffmann P, Fossum E, et al. Renal Sympathetic Denervation in Patients With Treatment-Resistant Hypertension After Witnessed Intake of Medication Before Qualifying Ambulatory Blood Pressure. Hypertension. 2013;62(3):526-32. DOI:10.1161/HYPERTENSIONAHA.113.01452.</mixed-citation><mixed-citation xml:lang="en">Fadl Elmula FE, Hoffmann P, Fossum E, et al. Renal Sympathetic Denervation in Patients With Treatment-Resistant Hypertension After Witnessed Intake of Medication Before Qualifying Ambulatory Blood Pressure. Hypertension. 2013;62(3):526-32. DOI:10.1161/HYPERTENSIONAHA.113.01452.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Fadl Elmula FE, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014;63(5):991-9. DOI:10.1161/HYPERTENSIONAHA.114.03246.</mixed-citation><mixed-citation xml:lang="en">Fadl Elmula FE, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014;63(5):991-9. DOI:10.1161/HYPERTENSIONAHA.114.03246.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Hjørnholm U, Aamodt M, Larstorp AC, et al. Directly Observed Therapy in Hypertension (DOT-HTN). In: Burnier M, editor. Drug Adherence in Hypertension and Cardiovascular Protection, Cham: Springer International Publishing; 2018, p. 57-85. DOI:10.1007/978-3-319-76593-8_6.</mixed-citation><mixed-citation xml:lang="en">Hjørnholm U, Aamodt M, Larstorp AC, et al. Directly Observed Therapy in Hypertension (DOT-HTN). In: Burnier M, editor. Drug Adherence in Hypertension and Cardiovascular Protection, Cham: Springer International Publishing; 2018, p. 57-85. DOI:10.1007/978-3-319-76593-8_6.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Hameed MA, Tebbit L, Jacques N, et al. Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens. 2016;30(2):83-9. DOI:10.1038/jhh.2015.38.</mixed-citation><mixed-citation xml:lang="en">Hameed MA, Tebbit L, Jacques N, et al. Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens. 2016;30(2):83-9. DOI:10.1038/jhh.2015.38.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Hjørnholm U, Larstorp ACK, Andersen MH, Høieggen A. Directly observed therapy prior to ambulatory blood pressure measurement (DOT-HTN) in uncontrolled hypertensive patients — Effect on blood pressure, safety and patient perception. Blood Press. 2019;28(5):327-35. DOI:10.1080/08037051.2019.1633907.</mixed-citation><mixed-citation xml:lang="en">Hjørnholm U, Larstorp ACK, Andersen MH, Høieggen A. Directly observed therapy prior to ambulatory blood pressure measurement (DOT-HTN) in uncontrolled hypertensive patients — Effect on blood pressure, safety and patient perception. Blood Press. 2019;28(5):327-35. DOI:10.1080/08037051.2019.1633907.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Heimark S, Eskås PA, Mariampillai JE, et al. Tertiary work-up of apparent treatment-resistant hypertension. Blood Press. 2016;25(5):312-8. DOI:10.3109/08037051.2016.1172865.</mixed-citation><mixed-citation xml:lang="en">Heimark S, Eskås PA, Mariampillai JE, et al. Tertiary work-up of apparent treatment-resistant hypertension. Blood Press. 2016;25(5):312-8. DOI:10.3109/08037051.2016.1172865.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Ионов М.В., Емельянов И.В., Вахрушев А.Д. и др. Опыт применения многоконтактных катетерных систем для проведения радиочастотной симпатической денервации почечных артерий у пациентов с резистентной артериальной гипертензией: непосредственные результаты вмешательства. Российский кардиологический журнал. 2022;27(2):4794. DOI:10.15829/1560-4071-2022-4794.</mixed-citation><mixed-citation xml:lang="en">Ionov MV, Emelyanov IV, Vakhrushev AD, et al. Experience of using multielectrode catheter systems to perform radiofrequency renal sympathetic denervation in patients with resistant hypertension: immediate procedural effects. Russian Journal of Cardiology. 2022;27(2):4794. (In Russ.) DOI:10.15829/1560-4071-2022-4794.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Pio-Abreu A, Trani-Ferreira F, Silva GV, et al. Directly observed therapy for resistant/refractory hypertension diagnosis and blood pressure control. Heart. 2022;108(24):1952-6. DOI:10.1136/heartjnl-2022-320802.</mixed-citation><mixed-citation xml:lang="en">Pio-Abreu A, Trani-Ferreira F, Silva GV, et al. Directly observed therapy for resistant/refractory hypertension diagnosis and blood pressure control. Heart. 2022;108(24):1952-6. DOI:10.1136/heartjnl-2022-320802.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Browne SH, Umlauf A, Tucker AJ, et al. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial. PLoS Med. 2019;16(10):e1002891. DOI:10.1371/journal.pmed.1002891.</mixed-citation><mixed-citation xml:lang="en">Browne SH, Umlauf A, Tucker AJ, et al. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial. PLoS Med. 2019;16(10):e1002891. DOI:10.1371/journal.pmed.1002891.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Ionov MV, Zhukova OV, Yudina YS, et al. Value-based approach to blood pressure telemonitoring and remote counseling in hypertensive patients. Blood Press. 2021;30(1):20-30. DOI:10.1080/08037051.2020.1813015.</mixed-citation><mixed-citation xml:lang="en">Ionov MV, Zhukova OV, Yudina YS, et al. Value-based approach to blood pressure telemonitoring and remote counseling in hypertensive patients. Blood Press. 2021;30(1):20-30. DOI:10.1080/08037051.2020.1813015.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Versmissen J, van Steenkiste J, Koch BCP, Peeters LEJ. “Under pressure”: The role of therapeutic drug monitoring in the treatment of hypertension. Br J Clin Pharmacol. 2024;90(8):1884-91. DOI:10.1111/bcp.16125.</mixed-citation><mixed-citation xml:lang="en">Versmissen J, van Steenkiste J, Koch BCP, Peeters LEJ. “Under pressure”: The role of therapeutic drug monitoring in the treatment of hypertension. Br J Clin Pharmacol. 2024;90(8):1884-91. DOI:10.1111/bcp.16125.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Iriarte G, Gonzalez O, Ferreirós N, et al. Validation of a fast liquid chromatography-UV method for the analysis of drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(27):3045-53. DOI:10.1016/j.jchromb.2009.07.018.</mixed-citation><mixed-citation xml:lang="en">Iriarte G, Gonzalez O, Ferreirós N, et al. Validation of a fast liquid chromatography-UV method for the analysis of drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(27):3045-53. DOI:10.1016/j.jchromb.2009.07.018.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Gonzalez O, Iriarte G, Rico E, et al. LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(28):2685-92. DOI:10.1016/j.jchromb.2010.07.026.</mixed-citation><mixed-citation xml:lang="en">Gonzalez O, Iriarte G, Rico E, et al. LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(28):2685-92. DOI:10.1016/j.jchromb.2010.07.026.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Brinker S, Pandey A, Ayers C, et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63(8):834-5. DOI:10.1016/j.jacc.2013.10.067.</mixed-citation><mixed-citation xml:lang="en">Brinker S, Pandey A, Ayers C, et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63(8):834-5. DOI:10.1016/j.jacc.2013.10.067.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Ceral J, Habrdova V, Vorisek V, et al. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34(1):87-90. DOI:10.1038/hr.2010.183.</mixed-citation><mixed-citation xml:lang="en">Ceral J, Habrdova V, Vorisek V, et al. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34(1):87-90. DOI:10.1038/hr.2010.183.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766-74. DOI:10.1097/HJH.0b013e32835e2286.</mixed-citation><mixed-citation xml:lang="en">Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766-74. DOI:10.1097/HJH.0b013e32835e2286.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927-37. DOI:10.1016/S0140-6736(22)02034-7. Erratum in: Lancet. 2023;401(10373):268. DOI:10.1016/S0140-6736(23)00119-8.</mixed-citation><mixed-citation xml:lang="en">Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927-37. DOI:10.1016/S0140-6736(22)02034-7. Erratum in: Lancet. 2023;401(10373):268. DOI:10.1016/S0140-6736(23)00119-8.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Strauch B, Petrák O, Zelinka T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31(12):2455-61. DOI:10.1097/HJH.0b013e3283652c61.</mixed-citation><mixed-citation xml:lang="en">Strauch B, Petrák O, Zelinka T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31(12):2455-61. DOI:10.1097/HJH.0b013e3283652c61.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Peeters LEJ, Feyz L, Boersma E, et al. Clinical Applicability of Monitoring Antihypertensive Drug Levels in Blood. Hypertension. 2020;76(1):80-6. DOI:10.1161/HYPERTENSIONAHA.120.15038.</mixed-citation><mixed-citation xml:lang="en">Peeters LEJ, Feyz L, Boersma E, et al. Clinical Applicability of Monitoring Antihypertensive Drug Levels in Blood. Hypertension. 2020;76(1):80-6. DOI:10.1161/HYPERTENSIONAHA.120.15038.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">de Jager RL, Maarseveen EM van, Bots ML, Blankestijn PJ.; SYMPATHY investigators. Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. Br J Clin Pharmacol. 2018;84(1):18-24. DOI:10.1111/bcp.13402.</mixed-citation><mixed-citation xml:lang="en">de Jager RL, Maarseveen EM van, Bots ML, Blankestijn PJ.; SYMPATHY investigators. Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. Br J Clin Pharmacol. 2018;84(1):18-24. DOI:10.1111/bcp.13402.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Bernieh D, Lawson G, Tanna S. Quantitative LC-HRMS determination of selected cardiovascular drugs, in dried blood spots, as an indicator of adherence to medication. J Pharm Biomed Anal. 2017;142:232-43. DOI:10.1016/j.jpba.2017.04.045.</mixed-citation><mixed-citation xml:lang="en">Bernieh D, Lawson G, Tanna S. Quantitative LC-HRMS determination of selected cardiovascular drugs, in dried blood spots, as an indicator of adherence to medication. J Pharm Biomed Anal. 2017;142:232-43. DOI:10.1016/j.jpba.2017.04.045.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Avataneo V, Fanelli E, De Nicolò A, et al. A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring. Front Pharmacol. 2022;12:755184. DOI:10.3389/fphar.2021.755184.</mixed-citation><mixed-citation xml:lang="en">Avataneo V, Fanelli E, De Nicolò A, et al. A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring. Front Pharmacol. 2022;12:755184. DOI:10.3389/fphar.2021.755184.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma JR, Dludla PV, Dwivedi G, Johnson R. Measurement Tools and Utility of Hair Analysis for Screening Adherence to Antihypertensive Medication. Glob Heart. 2023;18(1):17. DOI:10.5334/gh.1191.</mixed-citation><mixed-citation xml:lang="en">Sharma JR, Dludla PV, Dwivedi G, Johnson R. Measurement Tools and Utility of Hair Analysis for Screening Adherence to Antihypertensive Medication. Glob Heart. 2023;18(1):17. DOI:10.5334/gh.1191.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487- 97. DOI:10.1056/NEJMra050100.</mixed-citation><mixed-citation xml:lang="en">Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487- 97. DOI:10.1056/NEJMra050100.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Chung O, Vongpatanasin W, Bonaventura K, et al. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens. 2014;32(12):2411-21; discussion 2421. DOI:10.1097/HJH.0000000000000346.</mixed-citation><mixed-citation xml:lang="en">Chung O, Vongpatanasin W, Bonaventura K, et al. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens. 2014;32(12):2411-21; discussion 2421. DOI:10.1097/HJH.0000000000000346.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Nomura A, Tanigawa T, Kario K, Igarashi A. Cost-effectiveness of digital therapeutics for essential hypertension. Hypertens Res. 2022;45(10):1538-48. DOI:10.1038/s41440-022-00952-x.</mixed-citation><mixed-citation xml:lang="en">Nomura A, Tanigawa T, Kario K, Igarashi A. Cost-effectiveness of digital therapeutics for essential hypertension. Hypertens Res. 2022;45(10):1538-48. DOI:10.1038/s41440-022-00952-x.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta P, Patel P, Štrauch B, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension. 2017;70(5):1042-8. DOI:10.1161/HYPERTENSIONAHA.117.09631.</mixed-citation><mixed-citation xml:lang="en">Gupta P, Patel P, Štrauch B, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension. 2017;70(5):1042-8. DOI:10.1161/HYPERTENSIONAHA.117.09631.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Lane D, Patel P, Khunti K, Gupta P. Objective measures of non-adherence in cardiometabolic diseases: a review focused on urine biochemical screening. Patient Prefer Adherence. 2019;13:537-47. DOI:10.2147/PPA.S162215.</mixed-citation><mixed-citation xml:lang="en">Lane D, Patel P, Khunti K, Gupta P. Objective measures of non-adherence in cardiometabolic diseases: a review focused on urine biochemical screening. Patient Prefer Adherence. 2019;13:537-47. DOI:10.2147/PPA.S162215.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Lane D, Lawson A, Burns A, et al.; Endorsed by the European Society of Hypertension (ESH) Working Group on Cardiovascular Pharmacotherapy and Adherence. Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension. 2022;79(1):12-23. DOI:10.1161/HYPERTENSIONAHA.121.17596.</mixed-citation><mixed-citation xml:lang="en">Lane D, Lawson A, Burns A, et al.; Endorsed by the European Society of Hypertension (ESH) Working Group on Cardiovascular Pharmacotherapy and Adherence. Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension. 2022;79(1):12-23. DOI:10.1161/HYPERTENSIONAHA.121.17596.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Kichou B, Henine N, Himeur Y, et al. [Assessment of adherence to antihypertensive drugs in patients with resistant hypertension receiving optimal treatment]. Ann Cardiol Angeiol (Paris). 2019;68(4):264-8. (In French). DOI:10.1016/j.ancard.2019.07.002.</mixed-citation><mixed-citation xml:lang="en">Kichou B, Henine N, Himeur Y, et al. [Assessment of adherence to antihypertensive drugs in patients with resistant hypertension receiving optimal treatment]. Ann Cardiol Angeiol (Paris). 2019;68(4):264-8. (In French). DOI:10.1016/j.ancard.2019.07.002.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Zeijen VJM, Peeters LEJ, Asman A, et al. Quality-of-life and beliefs about medication in relation to a therapy adherence intervention in resistant hypertension: the Resistant HYpertension: MEasure to ReaCh Targets trial. J Hypertens. 2024;42(10):1687-94. DOI:10.1097/HJH.0000000000003780.</mixed-citation><mixed-citation xml:lang="en">Zeijen VJM, Peeters LEJ, Asman A, et al. Quality-of-life and beliefs about medication in relation to a therapy adherence intervention in resistant hypertension: the Resistant HYpertension: MEasure to ReaCh Targets trial. J Hypertens. 2024;42(10):1687-94. DOI:10.1097/HJH.0000000000003780.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Punt AM, Stienstra NA, van Kleef MEA, et al. Screening of cardiovascular agents in plasma with LC-MS/MS: A valuable tool for objective drug adherence assessment. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1121:103-10. DOI:10.1016/j.jchromb.2019.05.013.</mixed-citation><mixed-citation xml:lang="en">Punt AM, Stienstra NA, van Kleef MEA, et al. Screening of cardiovascular agents in plasma with LC-MS/MS: A valuable tool for objective drug adherence assessment. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1121:103-10. DOI:10.1016/j.jchromb.2019.05.013.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Sheppard JP, Albasri A, Gupta P, et al. Measuring adherence to antihypertensive medication using an objective test in older adults attending primary care: cross-sectional study. J Hum Hypertens. 2022;36(12):1106-12. DOI:10.1038/s41371-021-00646-w.</mixed-citation><mixed-citation xml:lang="en">Sheppard JP, Albasri A, Gupta P, et al. Measuring adherence to antihypertensive medication using an objective test in older adults attending primary care: cross-sectional study. J Hum Hypertens. 2022;36(12):1106-12. DOI:10.1038/s41371-021-00646-w.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Lawson AJ, Hameed MA, Brown R, et al. Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals. J Hypertens. 2020;38(6):1165-73. DOI:10.1097/HJH.0000000000002398.</mixed-citation><mixed-citation xml:lang="en">Lawson AJ, Hameed MA, Brown R, et al. Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals. J Hypertens. 2020;38(6):1165-73. DOI:10.1097/HJH.0000000000002398.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-42. DOI:10.1161/CIRCULATIONAHA.111.068064.</mixed-citation><mixed-citation xml:lang="en">Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-42. DOI:10.1161/CIRCULATIONAHA.111.068064.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Patel P, Gupta PK, White CM, et al. Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens. 2016;30(6):368-73. DOI:10.1038/jhh.2015.103.</mixed-citation><mixed-citation xml:lang="en">Patel P, Gupta PK, White CM, et al. Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens. 2016;30(6):368-73. DOI:10.1038/jhh.2015.103.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Velasco A, Chung O, Raza F, et al. Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension. J Clin Hypertens (Greenwich). 2015;17(9):713-9. DOI:10.1111/jch.12570.</mixed-citation><mixed-citation xml:lang="en">Velasco A, Chung O, Raza F, et al. Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension. J Clin Hypertens (Greenwich). 2015;17(9):713-9. DOI:10.1111/jch.12570.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Höcht C, Bertera FM, Mayer MA, Taira CA. Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers. Expert Opin Drug Metab Toxicol. 2010;6(2):199-211. DOI:10.1517/17425250903397381.</mixed-citation><mixed-citation xml:lang="en">Höcht C, Bertera FM, Mayer MA, Taira CA. Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers. Expert Opin Drug Metab Toxicol. 2010;6(2):199-211. DOI:10.1517/17425250903397381.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Родина Т.А., Мельников Е.С., Белков С.А. и др. Терапевтический лекарственный мониторинг нифедипина методом ВЭЖХ-МС/МС при лечении артериальной гипертензии. Биомедицина. 2017;(4):53-69]</mixed-citation><mixed-citation xml:lang="en">Rodina TA, Melnikov ES, Belkov SA, et al. Therapeutic drug monitoring of nifedipine by HPLC-MS/MS in treatment of arterial hypertension. Biomedicine. 2017;(4):53- 69. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Селезнев С.В., Якушин С.С., Мыльников П.Ю. и др. Терапевтический лекарственный мониторинг при неконтролируемой артериальной гипертензии: результаты пилотной части исследования. Российский медико-биологический вестник им. академика И.П. Павлова. 2023;31(2):195-202. DOI:10.17816/PAVLOVJ119880.</mixed-citation><mixed-citation xml:lang="en">Seleznev SV, Yаkushin SS, Mylnikov PY, et al. Therapeutic Drug Monitoring in Uncontrolled Arterial Hypertension: Result of the Pilot Part of Study. I.P. Pavlov Russian Medical Biological Herald.2023;31(2):195-202 (In Russ.) DOI:10.17816/PAVLOVJ119880.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Choudhry NK, Kronish IM, Vongpatanasin W, et al.; American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association. Hypertension. 2022;79(1):e1-14. DOI:10.1161/HYP.0000000000000203.</mixed-citation><mixed-citation xml:lang="en">Choudhry NK, Kronish IM, Vongpatanasin W, et al.; American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association. Hypertension. 2022;79(1):e1-14. DOI:10.1161/HYP.0000000000000203.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med. 1990;150(7):1509-10. DOI:10.1001/archinte.1990.00390190143023.</mixed-citation><mixed-citation xml:lang="en">Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med. 1990;150(7):1509-10. DOI:10.1001/archinte.1990.00390190143023.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Eskås PA, Heimark S, Eek Mariampillai J, et al. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension. Blood Press. 2016;25(4):199-205. DOI:10.3109/08037051.2015.1121706.</mixed-citation><mixed-citation xml:lang="en">Eskås PA, Heimark S, Eek Mariampillai J, et al. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension. Blood Press. 2016;25(4):199-205. DOI:10.3109/08037051.2015.1121706.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Durand H, Hayes P, Harhen B, et al. Medication adherence for resistant hypertension: Assessing theoretical predictors of adherence using direct and indirect adherence measures. Br J Health Psychol. 2018;23(4):949-66. DOI:10.1111/bjhp.12332.</mixed-citation><mixed-citation xml:lang="en">Durand H, Hayes P, Harhen B, et al. Medication adherence for resistant hypertension: Assessing theoretical predictors of adherence using direct and indirect adherence measures. Br J Health Psychol. 2018;23(4):949-66. DOI:10.1111/bjhp.12332.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Linicus Y, Kindermann I, Helfer AG, et al. Witnessed drug intake before planned denervation--always harmless? Int J Cardiol. 2015;179:125-6. DOI:10.1016/j.ijcard.2014.10.162.</mixed-citation><mixed-citation xml:lang="en">Linicus Y, Kindermann I, Helfer AG, et al. Witnessed drug intake before planned denervation--always harmless? Int J Cardiol. 2015;179:125-6. DOI:10.1016/j.ijcard.2014.10.162.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Halvorsen LV, Bergland OU, Søraas CL, et al. Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7‐Year Follow‐Up of Patients Considered Adherent by Directly Observed Therapy. J Am Heart Assoc. 2022;11(18):e025879. DOI:10.1161/JAHA.121.025879.</mixed-citation><mixed-citation xml:lang="en">Halvorsen LV, Bergland OU, Søraas CL, et al. Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7‐Year Follow‐Up of Patients Considered Adherent by Directly Observed Therapy. J Am Heart Assoc. 2022;11(18):e025879. DOI:10.1161/JAHA.121.025879.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Burnier M, Persu A, Azizi M, Prejbisz А. Patient perspectives on treatment adherence in hypertension: preliminary results of an ESH survey in five countries [abstract]. J Hypertens. 2022;40(Suppl 1):e61. DOI:10.1097/01.hjh.0000835756.15202.e5.</mixed-citation><mixed-citation xml:lang="en">Burnier M, Persu A, Azizi M, Prejbisz А. Patient perspectives on treatment adherence in hypertension: preliminary results of an ESH survey in five countries [abstract]. J Hypertens. 2022;40(Suppl 1):e61. DOI:10.1097/01.hjh.0000835756.15202.e5.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Лазебник Л.Б., Подкопаев Д.В., Комиссаренко И.А., Михеева О.М. Как повысить приверженность больных артериальной гипертензией к лечению? Артериальная гипертензия 2011;17(3):240-5] DOI: 10.18705/1607-419X-2011-17-3-240-245.</mixed-citation><mixed-citation xml:lang="en">Lazebnik LB, Podkopaev DV, Komissarenko IA, Mikheeva OM. How to increase compliance in hypertensive patients? Arterial Hypertension 2011;17(3):240- 5. (In Russ.) DOI: 10.18705/1607-419X-2011-17-3-240-245.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Burnier M, Prejbisz A, Weber T, et al. Hypertension healthcare professional beliefs and behaviour regarding patient medication adherence: a survey conducted among European Society of Hypertension Centres of Excellence. Blood Press. 2021;30(5):282-90. DOI:10.1080/08037051.2021.1963209.</mixed-citation><mixed-citation xml:lang="en">Burnier M, Prejbisz A, Weber T, et al. Hypertension healthcare professional beliefs and behaviour regarding patient medication adherence: a survey conducted among European Society of Hypertension Centres of Excellence. Blood Press. 2021;30(5):282-90. DOI:10.1080/08037051.2021.1963209.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
